Publications by authors named "Ashley Knights"

Claim this Profile
I
Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.
Michael T Bethune, Xiao-Hua Li, Jiaji Yu, Jami McLaughlin, Donghui Cheng, Ashley J Knights

Proc Natl Acad Sci U S A· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QuantiFERON-TB performance enhanced by novel Mycobacterium tuberculosis-specific antigens.
Monica Losi, Ashley J Knights, Francesca Mariani, Alfonso M Altieri, Gregorino Paone

Eur Respir J· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.
Katherine Woods, Ashley J Knights, Matthew Anaka, Ralf B Schittenhelm, Anthony W Purcell

J Immunother Cancer· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.
Laura J Vella, Anupama Pasam, Nektaria Dimopoulos, Miles Andrews, Ashley Knights

Cancer Immunol Res· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.
Rona Y Zhao, Nicole A Mifsud, Kun Xiao, Kok-Fei Chan, Sara Oveissi, Ashley J Knights

PLoS One· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy.
Ashley J Knights, Jitka Fucikova, Anupama Pasam, Sandra Koernig, Jonathan Cebon

Cancer Immunol Immunother· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma vaccines: developments over the past 10 years.
Oliver Klein, Christopher Schmidt, Ashley Knights, Ian D Davis, Weisan Chen

Expert Rev Vaccines· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
Neil C Robson, Tristan McAlpine, Ashley J Knights, Max Schnurr, Amanda Shin

Blood· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.
Jonathan Cebon, Ashley Knights, Lisa Ebert, Heather Jackson, Weisan Chen

Expert Rev Vaccines· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients.
Ashley J Knights, Natko Nuber, Christopher W Thomson, Olga de la Rosa, Elke Jäger

Cancer Immunol Immunother· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides.
Morgan G Mathieu, Ashley J Knights, Graham Pawelec, Catherine L Riley, Dorothee Wernet

Cancer Immunol Immunother· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin.
Laura Strauss, Theresa L Whiteside, Ashley Knights, Christoph Bergmann, Alexander Knuth

J Immunol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients.
Senta M Walton, Marco Gerlinger, Olga de la Rosa, Natko Nuber, Ashley Knights

J Immunol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells.
Ludmila Müller, Ashley Knights, Graham Pawelec

Hematol J· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of WT-1 peptides.
Ashley J Knights, Ludmila Müller, Graham Pawelec

Cancer Immunol Immunother· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol.
Ashley John Knights, Angeliki Zaniou, Robert C Rees, Graham Pawelec, Ludmila Müller

Cancer Immunol Immunother· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis